Skip to content

Opening book details…

Can I read Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study on EtoBox?

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study by Tjalf Ziemssen; Ann D. Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M. J. Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A. Singer; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators is a Medicine article available to read on EtoBox.

What is Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study about?

## Background Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active disease (HAD) by the American Academy of Neurology Practice Guidelines, and the label indication in Europe was recently restricted to the treatment of HAD patients. There is currently no consensus definition for HAD, and alemtuzumab efficacy across various HAD definitions has not been explored previously. ## Objectives In this post hoc analysis, we assess the efficacy and safety of alemtuzumab in Comparison of Alemtuzumab and Rebif^®^ Efficacy in Multiple Sclerosis (CARE-MS) trial patients who met criteria for at least one of four separate definitions of HAD (one primary and three alternatives). Over 2 years, alemtuzumab-treated HAD patients were compared with SC IFNB-1a-treated HAD patients, with additional 7-year follow-up in patients from the alemtuzumab arm. ## Methods Patients in the CARE-MS studies received either alemtuzumab (baseline: 5 days; 12 months later: 3 days) or SC IFN

Who reads Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Tjalf Ziemssen; Ann D. Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M. J. Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A. Singer; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
Publisher
Springer Science and Business Media LLC
Published
2020
Language
EN
Field
Medicine (Health Sciences)

More by Tjalf Ziemssen; Ann D. Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M. J. Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A. Singer; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators

Browse all works by Tjalf Ziemssen; Ann D. Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M. J. Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A. Singer; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators